Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRII-196 and BRII-198 in COVID-19
NCT04770467Phase 2Withdrawn
- Sponsor
- Brii Biosciences
- Start
- Feb 2021
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of amubarvimab, romlusevimab in coronavirus disease 2019 (COVID-19), sponsored by Brii Biosciences. Planned start Feb 2021; status: withdrawn.
02
Drugs
amubarvimabromlusevimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04770467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04770467.